GLP-1 agonists have already transformed the treatment landscape for diabetes and obesity, and their potential role in addiction medicine represents an exciting new frontier
Semaglutide may be a good starting option for individuals beginning GLP-1 treatment, while tirzepatide may be considered when additional appetite control or metabolic support is needed
Clinical trial participants showed improvements in systolic and diastolic blood pressure , triglycerides, LDL cholesterol, total cholesterol, HbA1c, and fasting glucose and insulin levels
Metabolic acidosis with intense renal disappointment (due to hepatorenal disorder) may create
Abrupt and strenuous physical exertion could result in muscle strain or microtears
Many facilities offer weight loss medications but leave insurance navigation to you